Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Kineret given within 6...

    Kineret given within 6 hrs improves outcome in ischemic stroke

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-04-06T20:00:03+05:30  |  Updated On 6 April 2018 8:00 PM IST
    Kineret given within 6 hrs improves outcome in ischemic stroke

    Stroke is one of the most common causes of disability in adults and a leading cause of death worldwide and it occurs when poor blood flow to the brain results in cell death. There are two main types of stroke ischemic, caused by lack of blood flow, and haemorrhagic, caused by bleeding in the brain.Dr.Craig J. Smith from the Greater Manchester Comprehensive Stroke Centre, Salford Royal NHS Foundation Trust, United Kingdom and associates conducted a double-blind trial to investigate whether subcutaneous administration of an anti-inflammatory drug IL-1Ra (Kineret)reduces the peripheral inflammatory response in acute ischemic stroke.They found that Kineret, a drug originally licensed for treating rheumatoid arthritis when given to patients in the early stages of an ischaemic stroke reduces harmful inflammation.The findings of the research have published their findings in the journal Stroke.




    The protein Interleukin-1 (IL-1), part of the body's defences increases inflammation and brain injury following a stroke.Kineret works by blocking the actions of IL-1 which is released into the body following injury caused by a stroke and reduces inflammation.


    The researchers in a randomized controlled Phase 2 Trial enrolled 80 Participants in the study and gave them six doses of the drug or placebo over three days. The first dose was given within 6 hours after the onset of the stroke symptoms.They measured inflammatory markers in the blood before treatment began and during study treatment.


    Professor Craig Smith said: "Though Strokes affect different people in different ways, for many people they have a devastating effect on their long-term health and well-being."Excessive inflammation after a stroke is known to be harmful and predicts a worse outcome in patients."We have shown that Kineret injections, started within six hours of stroke onset significantly reduces levels of inflammation in patients."


    The researchers concluded that IL-1Ra(Kineret) reduced plasma inflammatory markers which are known to be associated with worse clinical outcome in ischemic stroke. Subcutaneous IL-1Ra (Kineret)is safe and well tolerated. However, further experimental studies are required to investigate the efficacy and possible interactions of IL-1Ra with thrombolysis.


    The drug can be given quickly intravenously via injection or via a drip in ambulances on the way to a hospital. The brain loses around 2 million brain cells every minute during a stroke, so this could provide a major step forward in the fast and effective treatment of stroke.The research team have also shown that Kineret reduces inflammation and is safe in patients of subarachnoid haemorrhage.The drug is going to be tested in patients with intracerebral haemorrhage in coming times.


    For further reference log on to :

    http://stroke.ahajournals.org/content/early/2018/03/21/STROKEAHA.118.020750
    blood flowbrain cellsbrain injurycell deathDr Craig J Smithhaemorrhageinflammationischaemic strokeischemic strokejournal StrokeKineret injectionsperipheral inflammatoryplaceborheumatoid arthritisSubcutaneousthrombolysis

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok